Treatment of Renal Artery Clot (Renal Infarction)
Immediate systemic anticoagulation with unfractionated heparin followed by transition to long-term anticoagulation (warfarin or direct oral anticoagulants) is the primary treatment for renal infarction, with local thrombolysis or percutaneous thrombectomy reserved for cases presenting within 72 hours with complete main renal artery occlusion or bilateral disease.
Initial Management Approach
The cornerstone of treatment is anticoagulation therapy, which should be initiated as soon as the diagnosis is confirmed on contrast-enhanced CT imaging 1, 2, 3. The typical regimen involves:
- Acute phase: Unfractionated heparin or low-molecular-weight heparin (enoxaparin)
- Transition: To oral anticoagulation with warfarin or direct oral anticoagulants (apixaban) for long-term management 2, 3, 4
This approach has demonstrated preservation of renal function and prevention of infarction progression in recent case series 2, 3.
When to Consider Interventional Therapy
Local intra-arterial thrombolysis or percutaneous thrombectomy should be considered in specific high-risk scenarios:
- Complete main renal artery occlusion presenting within 72 hours of symptom onset 5
- Global renal infarction threatening total kidney loss 6
- Bilateral renal artery occlusion or occlusion in a solitary kidney
- Rapidly declining renal function despite anticoagulation
The evidence shows successful thrombolysis with streptokinase even at 72 hours post-occlusion 5, though earlier intervention yields better outcomes. Percutaneous thrombectomy with partial thrombus removal has been reported in cases of complete main renal artery occlusion 6.
Addressing the Underlying Cause
Identifying and treating the embolic source is critical to prevent recurrence:
Cardiogenic causes (55.7% of cases): Atrial fibrillation is the most common culprit 1, 7, 4
Hypercoagulable states (6.6% of cases): Complete thrombophilia workup 1, 3
Idiopathic cases (30.1%): Still require anticoagulation despite negative workup 1, 3
Blood Pressure Management
Renal infarction triggers renin release, causing hypertension. ACE inhibitors or angiotensin receptor blockers are recommended for blood pressure control 7.
Expected Outcomes and Follow-up
Despite aggressive treatment, renal infarction carries significant morbidity 1:
- 20.1% develop acute kidney injury during hospitalization
- 10.9% develop new-onset eGFR <60 mL/min/1.73m²
- 2.1% progress to end-stage renal disease
- 2.8% experience recurrent infarction
- 5% mortality during initial hospitalization
Critical pitfall: The nonspecific presentation (flank pain, hematuria, nausea) often mimics renal colic, leading to delayed diagnosis. Maintain high clinical suspicion in patients with atrial fibrillation, recent myocardial infarction, or cardiovascular risk factors presenting with acute flank pain 6, 2, 3.
Guideline Context
While the 2024 ESC guidelines 8 focus primarily on chronic renal artery stenosis rather than acute thrombotic occlusion, the principles of revascularization consideration apply: intervention is warranted when there are high-risk features (rapidly declining renal function, solitary kidney) and signs of kidney viability. For acute renal infarction, this translates to considering thrombolysis/thrombectomy in the early window (<72 hours) for complete occlusions.